CellaVision AB, which develops and sells image-based products for routine analysis of blood and other body fluids, has appointed Adam Morell new R&D Manager, starting on 1 August, 2008.
Adam Morell will be responsible for research and development of CellaVision's products and will be part of the management team. Adam Morell held different positions at CellaVision's R&D Department between 2001 and 2003 and since 2006. These included working as an industrial doctoral student, Technical Area Manager for Image Analysis - the company's core competence - and Patent Manager. He has also been a Ph.D. student at LTH/Malmö University and Head of Software Development at Agellis AB.
Adam Morell, 32 years old, holds a Master's degree in Engineering Physics, a Licentiate in Engineering in Applied Mathematics and a Bachelor's degree in Medicine. He replaces Christian Matson as R&D Manager.
CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.
For more information, please contact: